+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Blood Cancer Drugs Market by Drug Type, Disease Type, Treatment Type, End-User, Drug Formulation - Global Forecast 2025-2030- Product Image
Blood Cancer Drugs Market by Drug Type, Disease Type, Treatment Type, End-User, Drug Formulation - Global Forecast 2025-2030- Product Image
Sale

Blood Cancer Drugs Market by Drug Type, Disease Type, Treatment Type, End-User, Drug Formulation - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 196 Pages
  • October 2024
  • Region: Global
  • 360iResearch™
  • ID: 6010967
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Blood Cancer Drugs Market grew from USD 42.78 billion in 2023 to USD 45.98 billion in 2024. It is expected to continue growing at a CAGR of 9.90%, reaching USD 82.87 billion by 2030.

The blood cancer drugs market focuses on pharmaceutical treatments targeting various forms of blood cancers, including leukemia, lymphoma, and myeloma. These drugs are essential due to the aggressive nature of these cancers, which often require prompt and potent therapeutic interventions. The application of blood cancer drugs is wide-ranging, encompassing chemotherapies, targeted therapies, immunotherapies, and newer modalities like CAR-T cell therapy. End-use is primarily within hospitals, cancer treatment centers, and specialized clinics. Key influencing factors promoting growth include the increasing incidence of blood cancer globally, advances in drug development technologies, and a rising preference for personalized medicine. Furthermore, enhanced funding in healthcare sectors and increased research activities in oncologic sciences present significant market opportunities.

To leverage these opportunities, companies should focus on advancing R&D for targeted therapies and integrating AI in drug discovery processes. However, the market faces limitations such as high treatment costs, stringent regulatory requirements, and potential side effects of the drugs, which may impede faster adoption. Challenges also include patent expirations of major drug formulations and competition from generic drugs, which can lead to reduced revenue for top players. Innovation can be encouraged by investing in genomic studies to identify specific disease markers, developing biosimilars to reduce patient expenses, and enhancing drug delivery systems for better efficacy. Exploring collaborations with research institutions can further bolster advancements in precision medicine.

For business growth, thorough understanding of regulatory policies across different regions is vital, as harmonizing drug approval processes can streamline market entry. Given the dynamic nature of the market, stakeholder engagement is crucial to anticipate shifting demands and align strategic investments accordingly. Companies should continuously monitor technological trends and clinical trials to adapt swiftly. Key insight reveals that despite its challenges, the blood cancer drugs market holds considerable promise for transformative therapeutic breakthroughs, particularly in the realm of targeted and personalized treatments.

Understanding Market Dynamics in the Blood Cancer Drugs Market

The Blood Cancer Drugs Market is rapidly evolving, shaped by dynamic supply and demand trends. These insights provide companies with actionable intelligence to drive investments, develop strategies, and seize emerging opportunities. A comprehensive understanding of market dynamics also helps organizations mitigate political, geographical, technical, social, and economic risks while offering a clearer view of consumer behavior and its effects on manufacturing costs and purchasing decisions.
  • Market Drivers
    • Expanding healthcare infrastructure and access to treatment enhancing the blood cancer drugs market growth
    • Government initiatives and favorable policies supporting the development and accessibility of blood cancer drugs
    • Strategic collaborations and partnerships among key players accelerating advancements in blood cancer drug development
    • Increasing geriatric population and their susceptibility to blood cancers driving the market demand for blood cancer therapies
  • Market Restraints
    • Lack of awareness and early detection measures affects blood cancer treatment outcomes and market growth
    • Limited availability of specialized treatment facilities and healthcare professionals impacts patient care and market potential
  • Market Opportunities
    • Increasing demand for personalized medicine solutions in the blood cancer treatment market
    • Advancements in biologics and targeted therapies driving growth in blood cancer medication
    • Growing awareness and early diagnosis leading to higher treatment rates for blood cancer patients
  • Market Challenges
    • High competition among leading pharmaceutical companies affecting blood cancer drug pricing and market share
    • Stringent regulatory requirements and compliance hurdles impacting blood cancer drug innovation

Exploring Porter’s Five Forces for the Blood Cancer Drugs Market

Porter’s Five Forces framework further strengthens the insights of the Blood Cancer Drugs Market, delivering a clear and effective methodology for understanding the competitive landscape. This tool enables companies to evaluate their current competitive standing and explore strategic repositioning by assessing businesses’ power dynamics and market positioning. It is also instrumental in determining the profitability of new ventures, helping companies leverage their strengths, address weaknesses, and avoid potential pitfalls.

Applying PESTLE Analysis to the Blood Cancer Drugs Market

External macro-environmental factors deeply influence the performance of the Blood Cancer Drugs Market, and the PESTLE analysis provides a comprehensive framework for understanding these influences. By examining Political, Economic, Social, Technological, Legal, and Environmental elements, this analysis offers organizations critical insights into potential opportunities and risks. It also helps businesses anticipate changes in regulations, consumer behavior, and economic trends, enabling them to make informed, forward-looking decisions.

Analyzing Market Share in the Blood Cancer Drugs Market

The Blood Cancer Drugs Market share analysis evaluates vendor performance. This analysis provides a clear view of each vendor’s standing in the competitive landscape by comparing key metrics such as revenue, customer base, and other critical factors. Additionally, it highlights market concentration, fragmentation, and trends in consolidation, empowering vendors to make strategic decisions that enhance their market position.

Evaluating Vendor Success with the FPNV Positioning Matrix in the Blood Cancer Drugs Market

The Blood Cancer Drugs Market FPNV Positioning Matrix is crucial in evaluating vendors based on business strategy and product satisfaction levels. By segmenting vendors into four quadrants - Forefront (F), Pathfinder (P), Niche (N), and Vital (V) - this matrix helps users make well-informed decisions that best align with their unique needs and objectives in the market.

Strategic Recommendations for Success in the Blood Cancer Drugs Market

The Blood Cancer Drugs Market strategic analysis is essential for organizations aiming to strengthen their position in the global market. A comprehensive review of resources, capabilities, and performance helps businesses identify opportunities for improvement and growth. This approach empowers companies to navigate challenges in the increasingly competitive landscape, ensuring they capitalize on new opportunities and align with long-term success.

Key Company Profiles

The report delves into recent significant developments in the Blood Cancer Drugs Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Amgen Inc., AstraZeneca PLC, bluebird bio, Inc., Bristol-Myers Squibb Company, Celgene Corporation, Daiichi Sankyo Company, Limited, Eisai Co., Ltd., F. Hoffmann-La Roche Ltd, Gilead Sciences, Inc., GlaxoSmithKline plc, Incyte Corporation, Johnson & Johnson, Karyopharm Therapeutics Inc., Merck & Co., Inc., Novartis International AG, Pfizer Inc., Sanofi S.A., Seattle Genetics, Inc., and Takeda Pharmaceutical Company Limited.

Market Segmentation & Coverage

This research report categorizes the Blood Cancer Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:
  • Drug Type
    • Chemotherapy
      • Alkylating Agents
      • Anthracyclines
      • Antimetabolites
    • Immunotherapy
      • CAR T-Cell Therapy
      • Cytokines
      • Immune Checkpoint Inhibitors
    • Targeted Therapy
      • Monoclonal Antibodies
      • Proteasome Inhibitors
      • Tyrosine Kinase Inhibitors
  • Disease Type
    • Leukemia
      • Acute Lymphocytic Leukemia
      • Acute Myeloid Leukemia
      • Chronic Lymphocytic Leukemia
      • Chronic Myeloid Leukemia
    • Lymphoma
      • Hodgkin Lymphoma
      • Non-Hodgkin Lymphoma
    • Multiple Myeloma
    • Myelodysplastic Syndrome
  • Treatment Type
    • Consolidation Therapy
    • Induction Therapy
    • Maintenance Therapy
    • Palliative Therapy
  • End-User
    • Ambulatory Surgical Centers
    • Clinics
    • Homecare
    • Hospitals
  • Drug Formulation
    • Intramuscular
    • Intravenous
    • Oral
    • Subcutaneous
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report provides a detailed overview of the market, exploring several key areas:

  1. Market Penetration: A thorough examination of the current market landscape, featuring comprehensive data from leading industry players and analyzing their reach and influence across the market.
  2. Market Development: The report identifies significant growth opportunities in emerging markets and assesses expansion potential within established segments, providing a roadmap for future development.
  3. Market Diversification: In-depth coverage of recent product launches, untapped geographic regions, significant industry developments, and strategic investments reshaping the market landscape.
  4. Competitive Assessment & Intelligence: A detailed analysis of the competitive landscape, covering market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, technological advancements, and innovations in manufacturing by key market players.
  5. Product Development & Innovation: Insight into groundbreaking technologies, R&D efforts, and product innovations that will drive the market in future.

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

  1. What is the current size of the market, and how is it expected to grow?
  2. Which products, segments, and regions present the most attractive investment opportunities?
  3. What are the prevailing technology trends and regulatory factors influencing the market?
  4. How do top vendors rank regarding market share and competitive positioning?
  5. What revenue sources and strategic opportunities guide vendors' market entry or exit decisions?

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Expanding healthcare infrastructure and access to treatment enhancing the blood cancer drugs market growth
5.1.1.2. Government initiatives and favorable policies supporting the development and accessibility of blood cancer drugs
5.1.1.3. Strategic collaborations and partnerships among key players accelerating advancements in blood cancer drug development
5.1.1.4. Increasing geriatric population and their susceptibility to blood cancers driving the market demand for blood cancer therapies
5.1.2. Restraints
5.1.2.1. Lack of awareness and early detection measures affects blood cancer treatment outcomes and market growth
5.1.2.2. Limited availability of specialized treatment facilities and healthcare professionals impacts patient care and market potential
5.1.3. Opportunities
5.1.3.1. Increasing demand for personalized medicine solutions in the blood cancer treatment market
5.1.3.2. Advancements in biologics and targeted therapies driving growth in blood cancer medication
5.1.3.3. Growing awareness and early diagnosis leading to higher treatment rates for blood cancer patients
5.1.4. Challenges
5.1.4.1. High competition among leading pharmaceutical companies affecting blood cancer drug pricing and market share
5.1.4.2. Stringent regulatory requirements and compliance hurdles impacting blood cancer drug innovation
5.2. Market Segmentation Analysis
5.3. Porter’s Five Forces Analysis
5.3.1. Threat of New Entrants
5.3.2. Threat of Substitutes
5.3.3. Bargaining Power of Customers
5.3.4. Bargaining Power of Suppliers
5.3.5. Industry Rivalry
5.4. PESTLE Analysis
5.4.1. Political
5.4.2. Economic
5.4.3. Social
5.4.4. Technological
5.4.5. Legal
5.4.6. Environmental
6. Blood Cancer Drugs Market, by Drug Type
6.1. Introduction
6.2. Chemotherapy
6.2.1. Alkylating Agents
6.2.2. Anthracyclines
6.2.3. Antimetabolites
6.3. Immunotherapy
6.3.1. CAR T-Cell Therapy
6.3.2. Cytokines
6.3.3. Immune Checkpoint Inhibitors
6.4. Targeted Therapy
6.4.1. Monoclonal Antibodies
6.4.2. Proteasome Inhibitors
6.4.3. Tyrosine Kinase Inhibitors
7. Blood Cancer Drugs Market, by Disease Type
7.1. Introduction
7.2. Leukemia
7.2.1. Acute Lymphocytic Leukemia
7.2.2. Acute Myeloid Leukemia
7.2.3. Chronic Lymphocytic Leukemia
7.2.4. Chronic Myeloid Leukemia
7.3. Lymphoma
7.3.1. Hodgkin Lymphoma
7.3.2. Non-Hodgkin Lymphoma
7.4. Multiple Myeloma
7.5. Myelodysplastic Syndrome
8. Blood Cancer Drugs Market, by Treatment Type
8.1. Introduction
8.2. Consolidation Therapy
8.3. Induction Therapy
8.4. Maintenance Therapy
8.5. Palliative Therapy
9. Blood Cancer Drugs Market, by End-User
9.1. Introduction
9.2. Ambulatory Surgical Centers
9.3. Clinics
9.4. Homecare
9.5. Hospitals
10. Blood Cancer Drugs Market, by Drug Formulation
10.1. Introduction
10.2. Intramuscular
10.3. Intravenous
10.4. Oral
10.5. Subcutaneous
11. Americas Blood Cancer Drugs Market
11.1. Introduction
11.2. Argentina
11.3. Brazil
11.4. Canada
11.5. Mexico
11.6. United States
12. Asia-Pacific Blood Cancer Drugs Market
12.1. Introduction
12.2. Australia
12.3. China
12.4. India
12.5. Indonesia
12.6. Japan
12.7. Malaysia
12.8. Philippines
12.9. Singapore
12.10. South Korea
12.11. Taiwan
12.12. Thailand
12.13. Vietnam
13. Europe, Middle East & Africa Blood Cancer Drugs Market
13.1. Introduction
13.2. Denmark
13.3. Egypt
13.4. Finland
13.5. France
13.6. Germany
13.7. Israel
13.8. Italy
13.9. Netherlands
13.10. Nigeria
13.11. Norway
13.12. Poland
13.13. Qatar
13.14. Russia
13.15. Saudi Arabia
13.16. South Africa
13.17. Spain
13.18. Sweden
13.19. Switzerland
13.20. Turkey
13.21. United Arab Emirates
13.22. United Kingdom
14. Competitive Landscape
14.1. Market Share Analysis, 2023
14.2. FPNV Positioning Matrix, 2023
14.3. Competitive Scenario Analysis
14.4. Strategy Analysis & Recommendation
LIST OF FIGURES
FIGURE 1. BLOOD CANCER DRUGS MARKET RESEARCH PROCESS
FIGURE 2. BLOOD CANCER DRUGS MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
FIGURE 7. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 8. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY DISEASE TYPE, 2023 VS 2030 (%)
FIGURE 9. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY DISEASE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 10. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2030 (%)
FIGURE 11. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 12. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
FIGURE 13. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 14. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY DRUG FORMULATION, 2023 VS 2030 (%)
FIGURE 15. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY DRUG FORMULATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 16. AMERICAS BLOOD CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 17. AMERICAS BLOOD CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 18. UNITED STATES BLOOD CANCER DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 19. UNITED STATES BLOOD CANCER DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 20. ASIA-PACIFIC BLOOD CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 21. ASIA-PACIFIC BLOOD CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA BLOOD CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA BLOOD CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 24. BLOOD CANCER DRUGS MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 25. BLOOD CANCER DRUGS MARKET, FPNV POSITIONING MATRIX, 2023
LIST OF TABLES
TABLE 1. BLOOD CANCER DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. BLOOD CANCER DRUGS MARKET DYNAMICS
TABLE 7. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY ALKYLATING AGENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY ANTHRACYCLINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY ANTIMETABOLITES, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY CAR T-CELL THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY CYTOKINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY PROTEASOME INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY ACUTE LYMPHOCYTIC LEUKEMIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY ACUTE MYELOID LEUKEMIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY CHRONIC LYMPHOCYTIC LEUKEMIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY CHRONIC MYELOID LEUKEMIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY HODGKIN LYMPHOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY NON-HODGKIN LYMPHOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY MULTIPLE MYELOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY MYELODYSPLASTIC SYNDROME, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY CONSOLIDATION THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY INDUCTION THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY MAINTENANCE THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY PALLIATIVE THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY HOMECARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 51. AMERICAS BLOOD CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 52. AMERICAS BLOOD CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 53. AMERICAS BLOOD CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 54. AMERICAS BLOOD CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 55. AMERICAS BLOOD CANCER DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 56. AMERICAS BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
TABLE 57. AMERICAS BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 58. AMERICAS BLOOD CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 59. AMERICAS BLOOD CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 60. AMERICAS BLOOD CANCER DRUGS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
TABLE 61. AMERICAS BLOOD CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 62. ARGENTINA BLOOD CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 63. ARGENTINA BLOOD CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 64. ARGENTINA BLOOD CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 65. ARGENTINA BLOOD CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 66. ARGENTINA BLOOD CANCER DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 67. ARGENTINA BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
TABLE 68. ARGENTINA BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 69. ARGENTINA BLOOD CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 70. ARGENTINA BLOOD CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 71. ARGENTINA BLOOD CANCER DRUGS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
TABLE 72. BRAZIL BLOOD CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 73. BRAZIL BLOOD CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 74. BRAZIL BLOOD CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 75. BRAZIL BLOOD CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 76. BRAZIL BLOOD CANCER DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 77. BRAZIL BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
TABLE 78. BRAZIL BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 79. BRAZIL BLOOD CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 80. BRAZIL BLOOD CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 81. BRAZIL BLOOD CANCER DRUGS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
TABLE 82. CANADA BLOOD CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 83. CANADA BLOOD CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 84. CANADA BLOOD CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 85. CANADA BLOOD CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 86. CANADA BLOOD CANCER DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 87. CANADA BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
TABLE 88. CANADA BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 89. CANADA BLOOD CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 90. CANADA BLOOD CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 91. CANADA BLOOD CANCER DRUGS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
TABLE 92. MEXICO BLOOD CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 93. MEXICO BLOOD CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 94. MEXICO BLOOD CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 95. MEXICO BLOOD CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 96. MEXICO BLOOD CANCER DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 97. MEXICO BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
TABLE 98. MEXICO BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 99. MEXICO BLOOD CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 100. MEXICO BLOOD CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 101. MEXICO BLOOD CANCER DRUGS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
TABLE 102. UNITED STATES BLOOD CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 103. UNITED STATES BLOOD CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 104. UNITED STATES BLOOD CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 105. UNITED STATES BLOOD CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 106. UNITED STATES BLOOD CANCER DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 107. UNITED STATES BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
TABLE 108. UNITED STATES BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 109. UNITED STATES BLOOD CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 110. UNITED STATES BLOOD CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 111. UNITED STATES BLOOD CANCER DRUGS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
TABLE 112. UNITED STATES BLOOD CANCER DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 113. ASIA-PACIFIC BLOOD CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 114. ASIA-PACIFIC BLOOD CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 115. ASIA-PACIFIC BLOOD CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 116. ASIA-PACIFIC BLOOD CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 117. ASIA-PACIFIC BLOOD CANCER DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 118. ASIA-PACIFIC BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
TABLE 119. ASIA-PACIFIC BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 120. ASIA-PACIFIC BLOOD CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 121. ASIA-PACIFIC BLOOD CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 122. ASIA-PACIFIC BLOOD CANCER DRUGS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
TABLE 123. ASIA-PACIFIC BLOOD CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 124. AUSTRALIA BLOOD CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 125. AUSTRALIA BLOOD CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 126. AUSTRALIA BLOOD CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 127. AUSTRALIA BLOOD CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 128. AUSTRALIA BLOOD CANCER DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 129. AUSTRALIA BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
TABLE 130. AUSTRALIA BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 131. AUSTRALIA BLOOD CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 132. AUSTRALIA BLOOD CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 133. AUSTRALIA BLOOD CANCER DRUGS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
TABLE 134. CHINA BLOOD CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 135. CHINA BLOOD CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 136. CHINA BLOOD CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 137. CHINA BLOOD CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 138. CHINA BLOOD CANCER DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 139. CHINA BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
TABLE 140. CHINA BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 141. CHINA BLOOD CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 142. CHINA BLOOD CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 143. CHINA BLOOD CANCER DRUGS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
TABLE 144. INDIA BLOOD CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 145. INDIA BLOOD CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 146. INDIA BLOOD CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 147. INDIA BLOOD CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 148. INDIA BLOOD CANCER DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 149. INDIA BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
TABLE 150. INDIA BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 151. INDIA BLOOD CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 152. INDIA BLOOD CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 153. INDIA BLOOD CANCER DRUGS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
TABLE 154. INDONESIA BLOOD CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 155. INDONESIA BLOOD CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 156. INDONESIA BLOOD CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 157. INDONESIA BLOOD CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 158. INDONESIA BLOOD CANCER DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 159. INDONESIA BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
TABLE 160. INDONESIA BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 161. INDONESIA BLOOD CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 162. INDONESIA BLOOD CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 163. INDONESIA BLOOD CANCER DRUGS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
TABLE 164. JAPAN BLOOD CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 165. JAPAN BLOOD CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 166. JAPAN BLOOD CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 167. JAPAN BLOOD CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 168. JAPAN BLOOD CANCER DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 169. JAPAN BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
TABLE 170. JAPAN BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 171. JAPAN BLOOD CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 172. JAPAN BLOOD CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 173. JAPAN BLOOD CANCER DRUGS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
TABLE 174. MALAYSIA BLOOD CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 175. MALAYSIA BLOOD CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 176. MALAYSIA BLOOD CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 177. MALAYSIA BLOOD CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 178. MALAYSIA BLOOD CANCER DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 179. MALAYSIA BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
TABLE 180. MALAYSIA BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 181. MALAYSIA BLOOD CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 182. MALAYSIA BLOOD CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 183. MALAYSIA BLOOD CANCER DRUGS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
TABLE 184. PHILIPPINES BLOOD CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 185. PHILIPPINES BLOOD CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 186. PHILIPPINES BLOOD CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 187. PHILIPPINES BLOOD CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 188. PHILIPPINES BLOOD CANCER DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 189. PHILIPPINES BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
TABLE 190. PHILIPPINES BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 191. PHILIPPINES BLOOD CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 192. PHILIPPINES BLOOD CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 193. PHILIPPINES BLOOD CANCER DRUGS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
TABLE 194. SINGAPORE BLOOD CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 195. SINGAPORE BLOOD CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 196. SINGAPORE BLOOD CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 197. SINGAPORE BLOOD CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 198. SINGAPORE BLOOD CANCER DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 199. SINGAPORE BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
TABLE 200. SINGAPORE BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 201. SINGAPORE BLOOD CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 202. SINGAPORE BLOOD CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 203. SINGAPORE BLOOD CANCER DRUGS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
TABLE 204. SOUTH KOREA BLOOD CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 205. SOUTH KOREA BLOOD CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 206. SOUTH KOREA BLOOD CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 207. SOUTH KOREA BLOOD CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 208. SOUTH KOREA BLOOD CANCER DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 209. SOUTH KOREA BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
TABLE 210. SOUTH KOREA BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 211. SOUTH KOREA BLOOD CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 212. SOUTH KOREA BLOOD CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 213. SOUTH KOREA BLOOD CANCER DRUGS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
TABLE 214. TAIWAN BLOOD CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 215. TAIWAN BLOOD CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 216. TAIWAN BLOOD CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 217. TAIWAN BLOOD CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 218. TAIWAN BLOOD CANCER DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 219. TAIWAN BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
TABLE 220. TAIWAN BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 221. TAIWAN BLOOD CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 222. TAIWAN BLOOD CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 223. TAIWAN BLOOD CANCER DRUGS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
TABLE 224. THAILAND BLOOD CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 225. THAILAND BLOOD CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 226. THAILAND BLOOD CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 227. THAILAND BLOOD CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 228. THAILAND BLOOD CANCER DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 229. THAILAND BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
TABLE 230. THAILAND BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 231. THAILAND BLOOD CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 232. THAILAND BLOOD CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 233. THAILAND BLOOD CANCER DRUGS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
TABLE 234. VIETNAM BLOOD CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 235. VIETNAM BLOOD CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 236. VIETNAM BLOOD CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 237. VIETNAM BLOOD CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 238. VIETNAM BLOOD CANCER DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 239. VIETNAM BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
TABLE 240. VIETNAM BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 241. VIETNAM BLOOD CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 242. VIETNAM BLOOD CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 243. VIETNAM BLOOD CANCER DRUGS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
TABLE 244. EUROPE, MIDDLE EAST & AFRICA BLOOD CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 245. EUROPE, MIDDLE EAST & AFRICA BLOOD CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 246. EUROPE, MIDDLE EAST & AFRICA BLOOD CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 247. EUROPE, MIDDLE EAST & AFRICA BLOOD CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 248. EUROPE, MIDDLE EAST & AFRICA BLOOD CANCER DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 249. EUROPE, MIDDLE EAST & AFRICA BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
TABLE 250. EUROPE, MIDDLE EAST & AFRICA BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 251. EUROPE, MIDDLE EAST & AFRICA BLOOD CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 252. EUROPE, MIDDLE EAST & AFRICA BLOOD CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 253. EUROPE, MIDDLE EAST & AFRICA BLOOD CANCER DRUGS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
TABLE 254. EUROPE, MIDDLE EAST & AFRICA BLOOD CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 255. DENMARK BLOOD CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 256. DENMARK BLOOD CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 257. DENMARK BLOOD CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 258. DENMARK BLOOD CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 259. DENMARK BLOOD CANCER DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 260. DENMARK BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
TABLE 261. DENMARK BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 262. DENMARK BLOOD CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 263. DENMARK BLOOD CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 264. DENMARK BLOOD CANCER DRUGS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
TABLE 265. EGYPT BLOOD CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 266. EGYPT BLOOD CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 267. EGYPT BLOOD CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 268. EGYPT BLOOD CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 269. EGYPT BLOOD CANCER DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 270. EGYPT BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
TABLE 271. EGYPT BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 272. EGYPT BLOOD CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 273. EGYPT BLOOD CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 274. EGYPT BLOOD CANCER DRUGS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
TABLE 275. FINLAND BLOOD CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 276. FINLAND BLOOD CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 277. FINLAND BLOOD CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 278. FINLAND BLOOD CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 279. FINLAND BLOOD CANCER DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 280. FINLAND BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
TABLE 281. FINLAND BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 282. FINLAND BLOOD CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 283. FINLAND BLOOD CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 284. FINLAND BLOOD CANCER DRUGS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
TABLE 285. FRANCE BLOOD CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 286. FRANCE BLOOD CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 287. FRANCE BLOOD CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 288. FRANCE BLOOD CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 289. FRANCE BLOOD CANCER DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 290. FRANCE BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
TABLE 291. FRANCE BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 292. FRANCE BLOOD CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 293. FRANCE BLOOD CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 294. FRANCE BLOOD CANCER DRUGS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
TABLE 295. GERMANY BLOOD CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 296. GERMANY BLOOD CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 297. GERMANY BLOOD CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 298. GERMANY BLOOD CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 299. GERMANY BLOOD CANCER DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 300. GERMANY BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
TABLE 301. GERMANY BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 302. GERMANY BLOOD CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 303. GERMANY BLOOD CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 304. GERMANY BLOOD CANCER DRUGS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
TABLE 305. ISRAEL BLOOD CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 306. ISRAEL BLOOD CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 307. ISRAEL BLOOD CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 308. ISRAEL BLOOD CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 309. ISRAEL BLOOD CANCER DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 310. ISRAEL BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
TABLE 311. ISRAEL BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 312. ISRAEL BLOOD CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 313. ISRAEL BLOOD CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 314. ISRAEL BLOOD CANCER DRUGS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
TABLE 315. ITALY BLOOD CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 316. ITALY BLOOD CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 317. ITALY BLOOD CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 318. ITALY BLOOD CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 319. ITALY BLOOD CANCER DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 320. ITALY BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
TABLE 321. ITALY BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 322. ITALY BLOOD CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 323. ITALY BLOOD CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 324. ITALY BLOOD CANCER DRUGS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
TABLE 325. NETHERLANDS BLOOD CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 326. NETHERLANDS BLOOD CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 327. NETHERLANDS BLOOD CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 328. NETHERLANDS BLOOD CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 329. NETHERLANDS BLOOD CANCER DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 330. NETHERLANDS BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
TABLE 331. NETHERLANDS BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 332. NETHERLANDS BLOOD CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 333. NETHERLANDS BLOOD CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 334. NETHERLANDS BLOOD CANCER DRUGS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
TABLE 335. NIGERIA BLOOD CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 336. NIGERIA BLOOD CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 337. NIGERIA BLOOD CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 338. NIGERIA BLOOD CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 339. NIGERIA BLOOD CANCER DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 340. NIGERIA BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
TABLE 341. NIGERIA BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 342. NIGERIA BLOOD CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 343. NIGERIA BLOOD CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 344. NIGERIA BLOOD CANCER DRUGS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
TABLE 345. NORWAY BLOOD CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 346. NORWAY BLOOD CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 347. NORWAY BLOOD CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 348. NORWAY BLOOD CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 349. NORWAY BLOOD CANCER DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 350. NORWAY BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
TABLE 351. NORWAY BLOOD CANCER DRUGS MARKET SIZE, BY

Companies Mentioned

The leading players in the Blood Cancer Drugs market, which are profiled in this report, include:
  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca PLC
  • bluebird bio, Inc.
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • Daiichi Sankyo Company, Limited
  • Eisai Co., Ltd.
  • F. Hoffmann-La Roche Ltd
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Incyte Corporation
  • Johnson & Johnson
  • Karyopharm Therapeutics Inc.
  • Merck & Co., Inc.
  • Novartis International AG
  • Pfizer Inc.
  • Sanofi S.A.
  • Seattle Genetics, Inc.
  • Takeda Pharmaceutical Company Limited

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages196
PublishedOctober 2024
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 45.98 Billion
Forecasted Market Value ( USD ) by 2030 $ 82.87 Billion
Compound Annual Growth Rate9.9%
Regions CoveredGlobal
No. of Companies Mentioned21

Related Topics

Related Reports

Blood Cancer Drugs Global Market Report 2024 - Product Image

Blood Cancer Drugs Global Market Report 2024

  • Report
  • 175 Pages
  • Global
From
Doxorubicin Market Size, Share & Trends Analysis Report By Drug Formulation (Lyophilized Powder, Doxorubicin Injection), By Application, By Distribution Channel, By Region, And Segment Forecasts, 2024 - 2030 - Product Image

Doxorubicin Market Size, Share & Trends Analysis Report By Drug Formulation (Lyophilized Powder, Doxorubicin Injection), By Application, By Distribution Channel, By Region, And Segment Forecasts, 2024 - 2030

  • Report
  • 80 Pages
  • Global
From
Doxorubicin Market by Drug Formulation, Distribution Channel, Application - Global Forecast 2025-2030 - Product Image

Doxorubicin Market by Drug Formulation, Distribution Channel, Application - Global Forecast 2025-2030

  • Report
  • 199 Pages
  • Global
From
Capecitabine Market by Drug Formulation, Distribution Channel, End Users, Drug Type - Global Forecast 2025-2030 - Product Image

Capecitabine Market by Drug Formulation, Distribution Channel, End Users, Drug Type - Global Forecast 2025-2030

  • Report
  • 197 Pages
  • Global
From
Bruton's Tyrosine Kinase Hematological Cancer - Market Insight, Epidemiology and Market Forecast - 2034 - Product Image

Bruton's Tyrosine Kinase Hematological Cancer - Market Insight, Epidemiology and Market Forecast - 2034

  • Report
  • 200 Pages
  • Global
From

About the Blood Cancer Drug Market

The Blood Cancer Drug market is a subset of the Oncology Drugs market, which focuses on the treatment of cancer. Blood cancer drugs are used to treat a variety of blood cancers, including leukemia, lymphoma, and myeloma. These drugs are typically administered intravenously or orally, and may include chemotherapy, targeted therapy, and immunotherapy. Blood cancer drugs are designed to target cancer cells while minimizing damage to healthy cells, and may be used in combination with other treatments. The Blood Cancer Drug market is highly competitive, with a number of large pharmaceutical companies offering a range of treatments. Companies in the market include Novartis, Pfizer, Bristol-Myers Squibb, Celgene, and Merck. Show Less Read more

Copyright © 2002-2024 Research and Markets. All Rights Reserved.